Auria
Commercial- Indications
- Breast cancer screening
Company intelligence / Profile preview
Namida Lab has commercialized Auria—the first at-home biological breast health assessment using tear-based protein biomarkers to help women determine when to have a mammogram. While not a diagnostic tool for breast cancer itself, it provides risk stratification. The company previously had six additional tear-based oncology screening products in development but has recently shifted focus exclusively to Auria due to funding constraints. Early clinical results led to the product’s launch and recognition at the Edison Awards™.
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Namida Lab.